MTOR and non-small cell lung carcinoma: In non-small-cell lung cancer (NSCLC), resistance to agents such as paclitaxel (Taxol®) and cisplatin often involves epithelial–mesenchymal transition (EMT), activation of PI3K/AKT/mTOR and MAPK pathways, and alterations in microtubule-regulating proteins.